Abstract
Background
The significance of tumor-secreted cytokines in tumor development has gained substantial attention. Nevertheless, the precise role of tumor-related inflammatory cytokines in prostate cancer (PCa) remains ambiguous.
Objectives
To gain deeper insights into the inflammatory response in the process of PCa.
Methods
A total of 233 cases were collected, including 80 cases of prostate hyperplasia as disease control, 65 cases of postoperative prostate cancer and 36 cases of prostate cancer as PCa group. Additionally, 52 patients undergoing physical examinations during the same period were collected as the healthy control. The levels of 12 inflammatory cytokines in peripheral blood samples were analyzed using flow cytometric bead array technology. The levels of total prostate-specific antigen (TPSA) and free prostate-specific antigen (FPSA) in peripheral blood samples were analyzed using electrochemiluminescence technology.
Results
Our findings revealed significant increases in serum IL-8 levels in PCa group compared to the healthy control group. Additionally, IL-6, IL-10, IFN-γ and IL-12p70 levels were markedly elevated in the PCa group compared to the disease control group (all p < 0.05). Conversely, the level of IL-4, TNF-α, IL-1β, IL-17A and IFN-α were lower in the PCa group compared to those in control group. Following surgery, the concentration of IL-6 decreased; whereas, the concentrations of IL-4, TNF-α, IL-17A, IL-1β, IL-12p70, and IFN-α increased, demonstrating significant differences (p < 0.05). The differential upregulation of IL-6 or downregulation of IL-17A in peripheral blood exhibited diagnostic efficacy in PCa patients. Moreover, we observed a significant increase in IL-17A levels, accompanied by decreased of IL-2, IL-4, IL-10, TNF-a, IFN-γ, IL-1β, and IL-12P70 in patients with distant metastasis.
Conclusion
The peripheral blood cytokines are closely associated with the occurrence and development of prostate cancer, especially the serum levels of IL-6 and IL-17A may be useful as potential predictors of PCa diagnosis.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Prostate diseases are prevalent worldwide and are among the most common diseases of the male genitourinary system. PCa is the second most common cancer in men globally, with a mortality rate second only to lung cancer [1, 2]. Currently, there are multiple theories and hypotheses regarding the pathogenesis of PCa, but the exact causes are still unclear. However, the occurrence and development of the disease are often accompanied by inflammation [3]. The activation and recruitment of immune cells during the cellular inflammatory response can lead to the enrichment of cytokines and chemokines in the tumor microenvironment, thereby affecting cancer development [4,5,6].
After infection, sentinel immune cells in the body recognize invading pathogens and release inflammatory mediators, including cytokines [7,8,9]. Therefore, inflammation can promote the occurrence and progression of tumors by affecting the body’s immune system [5]. Multiple studies have shown that Th17 cells are considered an important group of cells that mediate inflammatory responses, and the release of interleukin-17A (IL-17A) by Th17 cells contributes to the maintenance of chronic inflammatory states and the development of a cancer-promoting microenvironment, which is closely related to the occurrence and development of PCa [10,11,12,13]. In addition, recent studies have indicated that interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) have different expressions in PCa tissues [14,15,16]. Another study found that interleukin-8 (IL-8) is also expressed in various cancers such as gastric cancer, esophageal cancer, and lung cancer to varying degrees [17,18,19,20]. Additionally, the remaining relevant reports include interleukin-2(IL-2), interleukin-4(IL-4), interleukin-5(IL-50), Interferon-α(IFN-α), Interferon-γ(IFN-γ), Interleukin-1β(IL-1β), and Interleukin-12p70(IL-12p70), all of which also associated with the occurrence and development of prostate disorders. IL-2 plays a critical role in immune responses, potentially influencing tumor development; IL-4, an anti-inflammatory cytokine, may regulate immune responses and tumor growth; IL-5 primarily regulates eosinophil proliferation, impacting tumor immune surveillance; IFN-α, widely studied in prostate disorders, enhances immune responses and inhibits tumor growth; IFN-γ, crucial for inflammation, influences prostate disorder progression; IL-1β, a pro-inflammatory cytokine, is implicated in tumor growth and metastasis as well as prostate disorders; IL-12p70 has been shown to inhibit prostate disorder growth and metastasis, suggesting its potential as an immunotherapy target.
These cytokines are complex responses stimulated during the tumor evolution process, and there have been few comprehensive reports on the comprehensive detection and analysis of cytokines in relation to the evolution of prostate cancer. Therefore, in this study, in order to better elucidate the relationship between prostate cancer and cytokines during the evolutionary process, we conducted a case–control study and systematically analyzed the concentration levels of cytokines in prostate-related diseases.
Materials and methods
Patients and specimens
This retrospective study received approval from the Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University, with ethics approval reference [No: 2021-K-301-01], and was conducted in accordance with the World Medical Association Declaration of Helsinki. The inclusion criteria were as follows: patients diagnosed and treated for prostate diseases at our hospital from January 2021 to April 2024, aged 30–90 years, and healthy individuals undergoing routine medical check-ups at the hospital during the same period. Exclusion criteria included underlying metabolic or infectious diseases, recent use of antibacterial drugs, history of other tumors, previous radiotherapy or chemotherapy. Additionally, patients with clear laboratory evidence of elevated levels of C-reactive protein (CRP), serum amyloid A (SAA), and procalcitonin (PCT), indicating signs of inflammation, were excluded.
Diagnostic criteria for prostate diseases
According to the 2022 National Comprehensive Cancer Network (NCCN) guidelines, prostate cancer is diagnosed based on prostate biopsy, with a positive diagnosis indicating prostate cancer [21]; benign prostatic hyperplasia is diagnosed based on rectal examination indicating enlarged and firm prostate, ultrasound showing an enlarged prostate, increased residual urine, and decreased urine flow rate; urinary frequency, urgency, dysuria, turbid urine, or the presence of white secretions and pain in the lower abdomen indicate prostatitis.
Sample collection
After standard aseptic procedures, 3 ml of residual serum from each participant was collected and immediately separated by centrifugation at 3000 rpm for 15 min, and the serum was stored in a − 80 °C freezer until further analysis.
Quantitative detection of cytokines, TPSA, and FPSA
Flow cytometric bead array technology was used with a cytokine multiplex detection kit (Saiji(Jiangxi) Biotechnology Co., Ltd, China, 20,231,001) on a BD FACS CANTO II flow cytometer to detect the levels of IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IFN-γ, IFN-α and TNF-α in peripheral blood samples. Electrochemiluminescence technology was used with a TPSA and FPSA Roche original detection kit on a Roche e601 electrochemiluminescence immunoassay analyzer (Roche (Shanghai) Co., Ltd., Switzerland) for detection.
Statistical analysis
Continuous variables were presented as the median and interquartile range. Given the non-normal distribution of the data and a small sample size, nonparametric tests were chosen. The Mann–Whitney U-test was used to compare differences in serum cytokine levels, as well as age, blood WBC counts, TPSA, FPAS, etc., between controls and PCa. Similarly, the Mann–Whitney U-test was employed to compare serum cytokine levels among prostate cancer patients at different stages of development. Multiple Mann–Whitney tests were used to compare serum cytokine levels between preoperative and postoperative PCa patients. Spearman correlation coefficients were calculated for correlation analysis between serum cytokine levels in all participants. Statistical significance was set at p < 0.05. All analyses were conducted using SPSS version 20.0 (IBM Corp., Armonk, NY, USA) and GraphPad Prism 9.0 (GraphPad, San Diego, CA, USA). Plotting was performed using R (version 4.2.1) and ggplot2.
Results
Participant characteristics
A total of 233 participants were included in this study, and all patients informed consent, including 80 cases of prostate hyperplasia as disease controls, while 65 cases of postoperative prostate cancer and 36 cases of prostate cancer as PCa group. Additionally, 52 participants were collected as the healthy controls (Flow chart as seen in Fig. 1). The clinical information of all subjects as shown in Table 1. The participants were age-matched, and there were no differences in white blood cell and neutrophil levels, indicating the absence of inflammatory response in both groups. While, as specific tumor markers for prostate cancer, TPSA and FPSA showed significantly increased expression in the tumor group, which is consistent with the expected results.
Cytokines characteristics in the participant
According to the hospital-recommended program, 12 candidate serum cytokines were selected for analysis. The heatmap displays the concentrations of these cytokines in the participants (Fig. 2A). The correlation heatmap showed their correlation between the 12 cytokines (Fig. 2B).
The distribution of cytokines in the peripheral blood of PCa patients
To compared the distribution of cytokines between PCa and the control group. The result as shown in Fig. 3, The levels of pro-inflammatory cytokines IL-8 were significantly increased in the peripheral blood of patients with PCa than in the healthy control group; while, IL-6, IL-10, IFN-γ and IL-12p70 were higher in patients with PCa than in the disease control group (all p < 0.05). There was no difference in the levels of IL-5 between the three groups (all p > 0.05). The surprising discovery is in the prostate cancer group, the concentrations of the inflammatory cytokines IL-4, TNF-α, IL-1β, and IFN-α were significantly lower than those in the healthy control group (all p < 0.05). The detail data shown in Table 1S.
The difference in serum cytokine distribution between patients undergoing prostate cancer surgery and those who have not undergone surgery
To analyze whether cytokines are associated with the surgical prognosis of prostate cancer patients, we compared the distribution of cytokines between prostate cancer patients and postoperative patients. In addition, we performed a more detailed analysis of the clinical data of PCa patients between these groups, and there were no significant differences in age, sex, BMI category, tumor location, tumor histology, and tumor size. Figure 4 shows the concentration of IL-6 decreased after surgery, showing a significant difference (p < 0.05). The concentrations of IL-4, TNF-α, IL-17A, IL-1β, IL-12P70 and IFN-α increased after surgery, showing significant differences (p < 0.05); while, the concentrations of the other cytokines showed no significant difference (all p > 0.05). In this part of the analysis indicating that these cytokines are influenced by the excision of the primary tumor.
Serum cytokines as possible diagnostic biomarkers for prostate cancer
To confirm the preceding findings, we performed ROC analysis. Figure 5 shows the ROC of the presence of PCa when cytokines were used. The area under the curve (AUC) of IL-6 and IL-17A in the diagnosis of prostate cancer patients were 0.721, and 0.710, respectively, demonstrates “good” capability for discriminating between patients with PCa and controls. Positive and negative predictive value, sensitivity and specificity of each cytokine’s diagnosis in PCa show in Table 2S.
The relationship between cytokine levels and metastasis, Gleason Score of prostate cancer patients
To further investigate the relevance of cytokines in prostate cancer development, we compared the distribution of various cytokines in the serum of patients with different Gleason scores and those with metastasis. The results revealed no statistically significant differences in cytokine distribution among prostate cancer patients with different Gleason scores (see in Table 3S). However, in patients with distant metastasis of prostate cancer, we found a significant increase in IL-17A levels; while, levels of cytokines IL-2, IL-4, IL-10, TNF-a, IFN-γ, IL-1β, and IL-12P70 were significantly decreased (As show in Table 2). This suggests that cytokines may contribute to the metastatic process of prostate cancer.
Discussion
PCa stands as the most prevalent malignant tumor among males and ranks as the fifth leading cause of cancer-related death globally [22]. Inflammation plays a key role in the occurrence and development of tumors, and prostate cancer is characterized by excessive expression of inflammation. Inflammatory cytokines are essential in the development of diseases into tumors and can directly act on tumor cells or indirectly exert multifaceted effects through the tumor microenvironment, promoting cancer cell proliferation [4,5,6].
Cytokines are small protein molecules secreted by various cells in the body and have a wide range of biological activities. They can be divided into pro-inflammatory and anti-inflammatory cytokines. Pro-inflammatory cytokines primarily secreted by lymphocytes and monocytes include IL-1β, IL-2, IL-5, IL-6, IL-8, IL-12p70, IL-17A, IFN-γ, IFN-α, and TNF-α. Anti-inflammatory cytokines include IL-4 and IL-10 [23,24,25].
In our study, after comprehensive analysis of 12 cytokines involved in prostate cancer and related diseases, we observed significant differences in many serum cytokine levels between prostate cancer patients and the control group. Specifically, concentrations of the inflammatory cytokines IL-8, IL-6, IL-10, INF-γ and IL-12P70, were significantly increase in the prostate cancer group compared to the control group; while, the concentrations of IL-4, IFN-α, TNF-α and IL-1β were significantly lower than those in the control group. Paul Katongole and others also found increased IL-6 levels in the serum of prostate cancer patients [26]. Additionally, other cytokines such as TNF-α, IL-8, and IL-1β have also been found to be associated with the development and progression of prostate cancer [27]. These cytokines can affect the growth and metastasis of prostate cancer by regulating inflammation, angiogenesis, and tumor cell proliferation in the tumor microenvironment. These cytokines are mainly secreted by T and B lymphocytes and are important components of the immune response, playing important roles in various biological functions, including immune response against bacterial infections [28]. These results indicate that inflammation often occurs during the evolution of prostate cancer and these indicators may be essential in diagnosing the disease.
Our study revealed a significant elevation in IL-6 concentration within the prostate cancer group compared to the disease control group, indicating a potential involvement of IL-6 in prostate cancer progression. This observation aligns with prior research documenting heightened IL-6 levels in the peripheral blood of individuals with prostate cancer [29,30,31]. IL-6 is recognized for its pivotal role in prostate-mediated immune responses, exerting influence on both humoral and cellular immune responses. It acts on B and T lymphocytes, stimulating their growth and differentiation, and contributes to inflammation induced by follicular Th cells [28, 29, 32].
Furthermore, we analyzed the changes in cytokine concentrations before and after prostate cancer surgery. We found that the concentration of IL-6 decreased after surgery; while, the concentrations of IL-4, TNF-α, IL-17A, IL-1β, IL-12P70 and IFN-α increased significantly. These findings suggest that surgery may have an impact on the inflammatory response and cytokine levels in prostate cancer patients. In other words, it is possible that the presence of the tumor leads to the continuous production of certain cytokines.
Additionally, our present data provide preliminary support for utilizing differential levels of IL-6 and IL-17A as indicators of existing PCa. Emerging evidence suggests that chemokines and cytokines are responsible for the pleiotropic actions in cancer, including the growth, angiogenesis, endothelial mesenchymal transition, leukocyte infiltration, and hormone escape for advanced PCa and therapy resistance. Previous studies have indicated that Melittin inhibits tumor cell migration and enhances cisplatin sensitivity by suppressing IL-17 signaling pathway gene LCN2 in castration-resistant prostate cancer [33].
Moreover, we have also found that multiple cytokines are correlated with the metastasis of prostate cancer. The literature on the association between cytokines and prostate cancer metastasis is quite extensive [34]. These studies typically involve measuring cytokine levels in patient serum or tissue samples and analyzing the relationship between these factors and prostate cancer metastasis and prognosis. Some studies also explore the role and mechanisms of specific cytokines in the pathway of prostate cancer metastasis [35]. These studies suggested cytokines hold significant potential in both the development of prostate cancer and its clinical monitoring.
Our study also has certain limitations. Firstly, although there is a biological relationship between inflammatory cytokines and prostate cancer and they have some statistical significance, our observations may have certain limitations. Before these results can be widely applied in clinical settings, it is necessary for us to repeatedly validate these conclusions by increasing the size of our research cohort. Secondly, our samples were collected at the same time point, and the cytokine concentrations were measured at a single time point, potentially overlooking potential changes over time. Thirdly, the relative imbalance in the collected samples across different groups may introduce certain biases to the conclusions.
In conclusion, our study provides insights into the distribution of peripheral blood cytokines in prostate cancer and related diseases, offering laboratory evidence for the relationship between disease occurrence, development, and prognosis. The changes in cytokine levels after prostate cancer surgery may also serve as targets for treatment. Nonetheless, our results contribute to the understanding of the role of cytokines in prostate cancer and provide potential avenues for further research and clinical applications.
References
Chen K, Jiang K, Tang L, Chen X, Hu J, Sun F (2021) Analysis of clinical trials on therapies for prostate cancer in mainland china and globally from 2010 to 2020. Front Oncol 11:647110. https://doi.org/10.3389/fonc.2021.647110
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660
Li W, Chen F, Gao H et al (2023) Cytokine concentration in peripheral blood of patients with colorectal cancer. Front Immunol 14:1175513. https://doi.org/10.3389/fimmu.2023.1175513
Kwon OJ, Zhang L, Ittmann MM, Xin L (2014) Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci USA 111:E592-600. https://doi.org/10.1073/pnas.1318157111
Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA (2014) Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. https://doi.org/10.1155/2014/149185
Yang KQ, Liu Y, Huang QH, Mo N, Zhang QY, Meng QG, Cheng JW (2017) Bone marrow-derived mesenchymal stem cells induced by inflammatory cytokines produce angiogenetic factors and promote prostate cancer growth. BMC Cancer 17:878. https://doi.org/10.1186/s12885-017-3879-z
Carty M, Guy C, Bowie AG (2021) Detection of viral infections by innate immunity. Biochem Pharmacol 183:114316. https://doi.org/10.1016/j.bcp.2020.114316
Kogut MH, Lee A, Santin E (2020) Microbiome and pathogen interaction with the immune system. Poult Sci 99:1906–1913. https://doi.org/10.1016/j.psj.2019.12.011
Kumar V (2020) Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets. Int Immunopharmacol 89:107087. https://doi.org/10.1016/j.intimp.2020.107087
Dai J, Lu Y, Roca H, Keller JM, Zhang J, McCauley LK, Keller ET (2017) Immune mediators in the tumor microenvironment of prostate cancer. Chin J Cancer 36:29. https://doi.org/10.1186/s40880-017-0198-3
Liu S, Liu F, Zhang B et al (2020) CD4(+) T helper 17 cell response of aged mice promotes prostate cancer cell migration and invasion. Prostate 80:764–776. https://doi.org/10.1002/pros.23990
Liu Y, Mikrani R, Xie D et al (2020) Chronic prostatitis/chronic pelvic pain syndrome and prostate cancer: study of immune cells and cytokines. Fundam Clin Pharmacol 34:160–172. https://doi.org/10.1111/fcp.12517
Wang X, Yang L, Huang F, Zhang Q, Liu S, Ma L, You Z (2017) Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells. Immunol Lett 184:7–14. https://doi.org/10.1016/j.imlet.2017.02.006
Deichaite I, Sears TJ, Sutton L et al (2022) Differential regulation of TNFα and IL-6 expression contributes to immune evasion in prostate cancer. J Transl Med 20:527. https://doi.org/10.1186/s12967-022-03731-x
Snyper NYF, Pike J, Ekwueme K, Shergill I, Hughes SF (2022) Selective biomarkers for inflammation and infection are associated with post-operative complications following transperineal template prostate biopsy (TTPB): a single-centre observational clinical pilot-study. Eur J Med Res 27:187. https://doi.org/10.1186/s40001-022-00807-8
Zhou J, Chen H, Wu Y, Shi B, Ding J, Qi J (2022) Plasma IL-6 and TNF-α levels correlate significantly with grading changes in localized prostate cancer. Prostate 82:531–539. https://doi.org/10.1002/pros.24299
Harshman LC, Wang VX, Hamid AA, Santone G, Drake CG, Carducci MA, DiPaola RS, Fichorova RN, Sweeney CJ (2020) Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805). Prostate 80:1429–1437. https://doi.org/10.1002/pros.24074
Ma Y, Fu Y, Fan X, Ji Q, Duan X, Wang Y, Zhang Y, Wang Z, Hao H (2023) FAK/IL-8 axis promotes the proliferation and migration of gastric cancer cells. Gastric Cancer. https://doi.org/10.1007/s10120-023-01384-3
Pastrez PRA, Barbosa AM, Mariano VS, Causin RL, Castro AG, Torrado E, Longatto-Filho A (2023) Interleukin-8 and interleukin-6 are biomarkers of poor prognosis in esophageal squamous cell carcinoma. Cancers (Basel) 15(4):1997. https://doi.org/10.3390/cancers15071997
Yi L, Wang X, Fu S, Yan Z, Ma T, Li S, Wei P, Zhang H, Wang J (2023) Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC. Discov Oncol 14:35. https://doi.org/10.1007/s12672-023-00641-2
Schaeffer EM, Srinivas S, Adra N et al (2022) NCCN guidelines® insights: prostate cancer, version 1.2023. J Natl Compr Cancer Netw JNCCN 20:1288–1298. https://doi.org/10.6004/jnccn.2022.0063
Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10:63–89. https://doi.org/10.14740/wjon1191
Crucitti A, Corbi M, Tomaiuolo PM, Fanali C, Mazzari A, Lucchetti D, Migaldi M, Sgambato A (2015) Laparoscopic surgery for colorectal cancer is not associated with an increase in the circulating levels of several inflammation-related factors. Cancer Biol Ther 16:671–677. https://doi.org/10.1080/15384047.2015.1026476
Propper DJ, Balkwill FR (2022) Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol 19:237–253. https://doi.org/10.1038/s41571-021-00588-9
Waldmann TA (2018) Cytokines in cancer immunotherapy. Cold Spring Harb Perspect Biol. https://doi.org/10.1101/cshperspect.a028472
Katongole P, Sande OJ, Nabweyambo S et al (2022) IL-6 and IL-8 cytokines are associated with elevated prostate-specific antigen levels among patients with adenocarcinoma of the prostate at the Uganda Cancer Institute. Future Oncol 18:661–667. https://doi.org/10.2217/fon-2021-0683
Garrido MM, Ribeiro RM, Krüger K, Pinheiro LC, Guimarães JT, Holdenrieder S (2021) Are proinflammatory cytokines relevant for the diagnosis of prostate cancer? Anticancer Res 41:3067–3073. https://doi.org/10.21873/anticanres.15090
Kim M, Reidenbach S, Schlechter T, Rothmann AC, Will R, Hofmann I (2023) Plakophilin 1 deficiency in prostatic tumours is correlated with immune cell recruitment and controls the up-regulation of cytokine expression post-transcriptionally. FEBS J 290:1907–1919. https://doi.org/10.1111/febs.16680
Chen S, Lu K, Hou Y et al (2023) YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6. J Immunother Cancer. https://doi.org/10.1136/jitc-2022-006020
Ene CV, Nicolae I, Geavlete B, Geavlete P, Ene CD (2022) IL-6 Signaling link between inflammatory tumor microenvironment and prostatic tumorigenesis. Anal Cell Pathol (Amst) 2022:5980387. https://doi.org/10.1155/2022/5980387
Zhang J, Ye Y, Xu Z, Luo M, Wu C, Zhang Y, Lv S, Wei Q (2023) Histone methyltransferase KMT2D promotes prostate cancer progression through paracrine IL-6 signaling. Biochem Biophys Res Commun 655:35–43. https://doi.org/10.1016/j.bbrc.2023.02.083
Han IH, Kim JH, Ryu JS (2023) Inflammatory response to trichomonas vaginalis in the pathogenesis of prostatitis and benign prostatic hyperplasia. Parasites Hosts Dis 61:2–14. https://doi.org/10.3347/phd.22160
Yan R, Dai W, Mao Y, Yu G, Li W, Shu M, Xu B (2023) Melittin inhibits tumor cell migration and enhances cisplatin sensitivity by suppressing IL-17 signaling pathway gene LCN2 in castration-resistant prostate cancer. Prostate 83:1430–1445. https://doi.org/10.1002/pros.24605
Yamaguchi M, Hashimoto K, Jijiwa M, Murata T (2023) The inflammatory macrophages repress the growth of bone metastatic human prostate cancer cells via TNF-α and IL-6 signaling: Involvement of cell signaling regulator regucalcin. Cell Signal 107:110663. https://doi.org/10.1016/j.cellsig.2023.110663
Fan H, Tang Z, Tian Y, Lv Q, Zeng F (2023) IL-8 produced via bidirectional communication between prostate cancer and m2 macrophages as a potential diagnostic and prognostic biomarker. Technol Cancer Res Treat 22:15330338231177808. https://doi.org/10.1177/15330338231177809
Acknowledgements
This research was supported by Zhejiang Medical and Health Science and Technology Plan Project (Fund No. 2022KY903); Science and Technology Plan Project of Wenzhou (Fund No. Y20210725).
Author information
Authors and Affiliations
Contributions
Xunjun Yang contributed to writing—original draft, methodology, investigation, formal analysis, funding acquisition, and resources. Rongfa Chen contributed to validation, methodology, and visualization. Linna Liu contributed to investigation and formal analysis. Hui Chen contributed to software. Chao Xing and Yilin Pang contributed to writing—review & editing. Tingting Zhang contributed to project administration, supervision, conceptualization, resources, and data curation. All authors agree to submit the article for publication.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Ethical approval
This study was reviewed and approved by the Second Affiliated Hospital of Wenzhou Medical University, with the approval number: No: 2021-K-301-01.
Informed consent
All participants provided informed consent to participate in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Chen, R., Liu, L., Chen, H. et al. Evaluation of the clinical application value of cytokine expression profiles in the differential diagnosis of prostate cancer. Cancer Immunol Immunother 73, 139 (2024). https://doi.org/10.1007/s00262-024-03723-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00262-024-03723-4